A Study in Moderate to Severe Rheumatoid Arthritis Participants
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily
(QD) is superior to placebo in the treatment of participants with moderately to severely
active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at
least 1 conventional disease-modifying antirheumatic drug (cDMARD)(cDMARD-IR [inadequate
response] participants) and who have not received a biologic disease-modifying antirheumatic
drug (DMARD).